Skip to content

    Jeena Sikho

    JSLLGood
    Healthcare·9 Feb 2026
    Management Summary

    Jeena Sikho reported a strong Q3 FY26, significantly outperforming previous periods with robust growth in revenue, EBITDA, and PAT. This was driven by increased patient volumes across all service lines and strong traction in Ayurvedic product sales, despite the quarter typically being weak for the healthcare sector. The company is aggressively pursuing product launches, expanding its bed capacity, and focusing on international growth and health insurance penetration to sustain its growth trajectory.

    Highlights

    8

    • Total operational income (Revenue) of ₹221.7 crores, up 92% YoY and 17% QoQ.

    • EBITDA reached ₹100.8 crores, marking a 240% YoY increase, with an EBITDA margin of 45%+.

    • Profit after tax (PAT) stood at ₹66.7 crores, reflecting a 400% YoY growth, with a PAT margin of 30%.

    • Basic EPS for the quarter was ₹5.37.

    • OPD and COD video consultation patients grew by 247% to 4.34 lakhs.

    • IPD patients increased by 84%, and day care patients by 139%.

    • Occupancy rate maintained at 58% despite Q3 being a weak quarter for the healthcare industry.

    • Target to launch 16 new products by December 31, 2026, and achieve ₹500 crores in OTC revenue in two financial years.

    Key financials

    Single quarter

    07 metrics
    1. 01Revenue₹221.7 Cr+92%YoY
    2. 02EBITDA₹100.8 Cr+2.4%YoY
    3. 03EBITDA Margin45%
    4. 04PAT₹66.7 Cr+4%YoY
    5. 05PAT Margin30%

    Segment breakdown

    FY25 Annual Revenue Breakdown
    ₹215 Cr Medicine Sales₹136 Cr Hospital Services₹118 Cr Government Services₹469 Cr Total Revenue54% Healthcare Share46% Medicine Share
    List

    Guidance & targets

    9
    CategoryTargetPriority
    Product
    New Product Launches
    16 products
    		High
    Capacity
    Total Beds
    7,000 to 10,000 beds
    		High
    Capacity
    Occupancy Rate
    70%-80%
    		High
    Capacity
    Company-owned Super Specialty Clinics
    5 to 10
    		High
    Revenue
    Diagnostics Turnover (Chandan)
    INR10 to INR15 crores
    		High
    Revenue
    OTC Revenue
    INR500 crores
    		High
    Volume
    Chandan Daily Sales
    5 lakh per day
    		High
    Profitability
    Profit
    INR1,000 crores
    		High
    Profitability
    Profit Growth
    4x to 5x
    		High

    Risks & concerns

    5
    RiskSeverity

    Payment issues and operational challenges with government business.

    Management is actively reducing exposure to government business due to problems with timely payments and complex protocols. — Management acknowledged

    medium

    Cyclical weakness in the healthcare industry during Q3 (Diwali, winter, New Year).

    Management anticipated this seasonal weakness and mitigated its impact by strategically increasing focus on product sales, leading to strong Q3 results. — Management acknowledged

    low

    Competition in the Ayurveda sector.

    Management believes their integrated model, focus on quality, customer trust, and comprehensive value chain (products, hospitals, diagnostics, international) differentiates them from competitors. — Analyst downplayed

    low

    Areas of Evasion(2)

    • FY26 revenue guidance
    • specific timeline for government portal improvements

    Q&A highlights

    3

    “Sir, I cannot control the government, right? That is the government's sector. When will the government do it? And why do I need to do government business? There are problems upon problems in government business. Money doesn't come on time.”

    Reveals management's cautious stance on government business due to payment delays, indicating a strategic shift towards private and insurance-based revenue.

    asked by Priyanshu Jain

    2 min read6 chapters

    Detailed Narrative

    01

    Exceptional Q3 FY26 Financial Performance

    Jeena Sikho reported a robust Q3 FY26, with total operational income reaching ₹221.7 crores, marking a significant 92% year-on-year and 17% quarter-on-quarter growth. EBITDA surged by 240% year-on-year to ₹100.8 crores, achieving a margin of over 45%. Profit after tax (PAT) saw an impressive 400% year-on-year increase to ₹66.7 crores, with a PAT margin of 30%. This strong performance, yielding a basic EPS of ₹5.37, was achieved despite Q3 typically being a weak period for the healthcare sector.

    02

    Strategic Product Launches and Distribution Expansion

    The company is aggressively expanding its product portfolio, targeting 16 new product launches by December 31, 2026. Its first OTC product, 'Pet Yakrit Pleeha Shuddhi Kit', has already achieved monthly sales exceeding ₹10 crores. Jeena Sikho has also finalized a key distribution agreement with Entero, aiming to reach 1 lakh medical stores across India and targeting ₹500 crores in OTC revenue within the next two financial years. This strategy is expected to significantly boost product sales and market penetration.

    03

    Robust Patient Growth and Capacity Expansion

    Jeena Sikho demonstrated strong patient growth, with OPD and COD video consultations increasing by 247% to 4.34 lakhs patients. IPD patients grew by 84%, and day care patients by 139%. The company maintained a 58% occupancy rate for its 2,290 operational beds, with a total of 11,313 patients admitted in Q3. Management plans to expand total bed capacity to 7,000-10,000 beds in the next 3-5 years, targeting a sustained occupancy rate of 70-80%.

    04

    International Expansion and Diagnostics Partnership Progress

    The company's international expansion is gaining momentum, with two day care centers operational in UAE and four more under construction in Dubai. Operations have also commenced in Kazakhstan and Nepal, with plans for US expansion underway. Domestically, the partnership with Chandan Diagnostics is progressing well, with 34 centers operational and a target to increase daily sales to 5 lakh, aiming for an annual turnover of ₹10-15 crores from diagnostics.

    05

    Shift Towards Wellness, Prevention, and Health Insurance Leverage

    Jeena Sikho is strategically focusing on wellness and preventive healthcare, aiming to educate the public on healthy living and launching preventive products like 'Nutri-Roz'. A significant development is the increasing reimbursement of Ayurveda treatments, including day care and medicines, by health insurance companies. This is expected to be a major growth driver, as health insurance currently accounts for less than 25% of their business, indicating substantial untapped potential.

    06

    Enhanced Corporate Governance and Employee Incentives

    To strengthen corporate governance and operational efficiency, Jeena Sikho has appointed Forvis Mazars as its internal auditor and Grant Thornton as its main auditor, alongside implementing international-level software like Salesforce and Oracle. A new 3-year ESOP policy has been introduced, with vesting at 20%, 30%, and 50% annually, designed to attract and retain top talent and align employee incentives with company profitability.

    This is an AI-generated summary of a publicly available earnings call transcript. It is for informational purposes only and does not constitute investment advice, a recommendation, or an endorsement. inve.money is not a SEBI-registered investment advisor. Please consult a qualified financial advisor before making any investment decisions.